1 / 3

Comprehensive Analysis of ASt2331 and CDDP Efficacy in Cancer Treatment

This report presents a detailed examination of the treatment outcomes associated with ASt2331, CDDP, and GEM in a specific study cohort. The findings show significant response rates, with ASt2331 combined with CDDP demonstrating a total efficacy of 17.0%. Additionally, the study analyzes PARP-related biomarkers, including intact PARP at 116 kDa and cleavage products like β-Aktin. The therapeutic impact is measured across various time intervals, providing insights into optimal administration schedules for enhanced patient outcomes.

mariah
Télécharger la présentation

Comprehensive Analysis of ASt2331 and CDDP Efficacy in Cancer Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ASt2331+MMC NS-K1+MMC ASt2331 NS-K1 total: 12.9% / 32.4% total: 8.4% / 11.0% total: 5.3% total: 10.5% 12.4 2.4 2.9 3.3 20.0 2.9 7.6 7.7 NS-K1+CDDP NS-K1+GEM ASt2331+GEM total: 17.0% / 18.2% total: 7.8% / 13.8% total: 27.7% / 19.9% total: 14.6% / 9.0% ASt2331+CDDP 4.7 2.8 3.2 3.7 15.2 6.2 10.6 14.5

  2. 24h Über-stand 4h 8h 16h 24h 48h PARP: intakt, 116kDa Spaltprodukt, 85kDa -Aktin, 42kDa

  3. -Aktin (42kDa) Pro-Caspase 3 (32kDa) 3 4 5 6 1 2 Pro-Caspase 3-Spaltprodukt (11kDa)

More Related